Parallelizing Drug Discovery: HPC Pipelines for Alzheimer's Molecular Docking and Simulation
By: Paul Ruiz Alliata , Diana Rubaga , Daniel Kumlin and more
Potential Business Impact:
Finds new medicines for brain diseases faster.
High-performance computing (HPC) is reshaping computational drug discovery by enabling large-scale, time-efficient molecular simulations. In this work, we explore HPC-driven pipelines for Alzheimer's disease drug discovery, focusing on virtual screening, molecular docking, and molecular dynamics simulations. We implemented a parallelised workflow using GROMACS with hybrid MPI-OpenMP strategies, benchmarking scaling performance across energy minimisation, equilibration, and production stages. Additionally, we developed a docking prototype that demonstrates significant runtime gains when moving from sequential execution to process-based parallelism using Python's multiprocessing library. Case studies on prolinamide derivatives and baicalein highlight the biological relevance of these workflows in targeting amyloid-beta and tau proteins. While limitations remain in data management, computational costs, and scaling efficiency, our results underline the potential of HPC to accelerate neurodegenerative drug discovery.
Similar Papers
Towards High-Performance and Portable Molecular Docking on CPUs through Vectorization
Distributed, Parallel, and Cluster Computing
Makes computer programs run faster on different chips.
On the Challenges of Energy-Efficiency Analysis in HPC Systems: Evaluating Synthetic Benchmarks and Gromacs
Distributed, Parallel, and Cluster Computing
Makes computer energy use easier to measure.
Scalable, Cloud-Based Simulations of Blood Flow and Targeted Drug Delivery in Retinal Capillaries
Fluid Dynamics
Lets scientists run big biology tests on the internet.